|
A Study of Peldesine (BCX-34) in HIV-Infected Patients Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on A Study of Peldesine (BCX-34) in HIV-Infected Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study of Peldesine (BCX-34) in HIV-Infected Patients Clinical research trials and A Study of Peldesine (BCX-34) in HIV-Infected Patients medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including A Study of Peldesine (BCX-34) in HIV-Infected Patients. A Study of Peldesine (BCX-34) in HIV-Infected Patients Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Study of Peldesine (BCX-34) in HIV-Infected Patients clinical trial. Participants oftentimes recieve the finest healthcare available for their A Study of Peldesine (BCX-34) in HIV-Infected Patients condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Peldesine (BCX-34) in HIV-Infected Patients  A Study of Peldesine (BCX-34) in HIV-Infected Patients
A Study of Peldesine (BCX-34) in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): BioCryst Pharmaceuticals ,
Synopsis: The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.
Details: Patients are given either BCX-35 or placebo for 14 or 28 days. Plasma viral load will be determined at the MTD.
Eligibility:
Study Type: Interventional, Treatment, Placebo Control, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documented HIV infection. - CD4 cell count greater than or equal to 300 cells/mm3 on 3 occasions prior to protocol treatment. - Plasma viral load by Roche Amplicor HIV Monitor assay greater than or equal to 2,000 RNA copies/ml and less than or equal to 50,000 RNA copies/ml on at least 2 occasions prior to protocol treatment. - Normal or non-diagnostic electrocardiogram. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Severe opportunistic infection or any other medical condition which in the opinion of the investigators is a contraindication to enrolling in this trial. - Severe lactose intolerance. Concurrent Medication: Excluded: Concomitant therapy with other medications having primary renal excretion (other than 3TC, ddC, and d4T). Prior Medication: Excluded: - Ongoing dideoxyinosine or other antiretroviral therapy except ZDV, 3TC, ddC, d4T, saquinavir, ritonavir, indinavir, and nelfinavir within 2 weeks of study. - Participation in a study of any systemic experimental drug within the last 2 months. Required: Ongoing (at least 4 weeks) stable dosage of zidovudine (ZDV) and lamivudine (3TC), ZDV and stavudine (d4T), ZDV and zalcitabine (ddC), d4T and 3TC, ZDV alone, or ddC alone, or in combination with saquinavir, ritonavir, indinavir, or nelfinavir.
Total Enrollment:
Location and Contact Information:
Saint Francis Mem Hosp / HIV Care Unit
San Francisco, California, 94109
United States
Additional Information:
Study ID Numbers: 301A; 96-009
Study Start Date:
Record last reviewed: September 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002237
Other Hiv Infections Studies:
1. A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP
2. A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
3. A Study of the Safety and Tolerance of Long-Term Therapy with Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons with AIDS
4. A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
5. The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients with No Symptoms of Infection
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Study of Peldesine (BCX-34) in HIV-Infected Patients
|
|
|
|
|
|
|
|
